Celgene, Mayo Clinic and GV-backed Evelo has added $47.5m to its coffers, seven months after closing a $50m series B round.

Existing investor Illumina Ventures is among the participants that have contributed to the gut-brain axis drug developer's series B round.

Iqvia led a round backed by Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health and Memorial Sloan Kettering Cancer Center.

Taiho Ventures has come on board as an investor, in a round that increased the cancer drug developer's total funding to almost $120m.

UNC Chapel Hill spinout Liquidia has secured an initial $25.5m and is aiming for a $53.3m close.

The city of Phoenix has approved funding for a medical technology accelerator, dubbed Innovention, which will be operated in collaboration with University of Arizona.

PPD and Siemens-backed pain management drug particle developer Liquidia has secured an initial $25.5m and is aiming for a $53.3m close.

Viking Global Investors led the Novo-backed company's latest round, which will be used to commercialise its ablation-based BPH treatment.

Stanford University is set to exit the cancer immunotherapy developer, which has filed for a $100m initial public offering.